Hengrui Medicine: Subsidiary HRS-5346 Tablet Included in List of Breakthrough Therapies

Hengrui Pharmaceutical announced that its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd.'s HRS-5346 tablets have been included in the list of breakthrough therapies by the National Medical Products Administration Drug Evaluation Center. HRS-5346 is an Lp oral small molecule inhibitor intended for the treatment of elevated levels of lipoproteins. Currently, there are no similar products approved for sale domestically or abroad.